LumiraDx to Present on Impact of Its Next-Generation Microfluidic Technology at AACC 2022

Speaking during the session will be lead author on a number of research papers reviewing the SARS-CoV-2 Ag test, Paul Drain, MD, MPH, FIDSA, Associate Professor in the Departments of Global Health, Medicine (Infectious Diseases), and Epidemiology at the University of Washington, along with Brian DuChateau, Ph.D., D (ABMLI), VP of Clinical and Scientific Affairs, LumiraDx. Key findings in the study revealed that the LumiraDx SARS-CoV-2 Ag test showed a 97.6% positive agreement to RT PCR in patients up to 12 days following symptom onset, and 100% PPA up to Ct 33.

In addition to hosting the workshop, LumiraDx will be exhibiting in the show’s main exhibition hall at booth #4821, and will be presenting its poster abstract ‘Correlation of the Rapid, Point-of-Care LumiraDx SARS-CoV-2 Antibody Test to Other SARS-CoV-2 Antibody Tests and to Viral Neutralization’ (poster B-195) and be featured in a poster abstract by John’s Hopkins Hospital ‘Implementation of POCT COVID-19 Testing Using a LumiraDx SARS-CoV-2 Testing Platform in Patient and Employee Testing Environments’ (poster A-142.)

“Studies have shown that point of care antigen tests with sufficient sensitivity and specificity can facilitate diagnosis, treatment, and mitigate reliance on slower, conventional laboratory-based testing and infrastructure,” said Dr. DuChateau. “However, the COVID-19 pandemic not only demonstrated the need for this type of testing, but also showed how quick result turn-around-time can mitigate rates of infection. LumiraDx’s actively controlled microfluidic testing technology brings lab-comparable performance to the point-of-need, supporting several unique use-cases during the pandemic and beyond.”